Clinical Rheumatology

, Volume 32, Issue 9, pp 1301–1307 | Cite as

Human papillomavirus vaccine and systemic lupus erythematosus

  • Mariele Gatto
  • Nancy Agmon-Levin
  • Alessandra Soriano
  • Raffaele Manna
  • Ramit Maoz-Segal
  • Shaye Kivity
  • Andrea Doria
  • Yehuda Shoenfeld
Original Article

Abstract

To investigate the association between human papillomavirus (HPV) vaccination and autoimmune manifestations compatible with systemic lupus erythematosus (SLE) or SLE-like disease, the medical history of six women who presented with SLE or SLE-like disease following HPV immunization was collected. Data regarding type of vaccine, number of immunization, family and personal, clinical and serological features, as well as response to treatments were analyzed. In the reported cases, several common features were observed, such as personal or familial susceptibility to autoimmunity or adverse response to a prior dose of the vaccine, both of which may be associated with a higher risk of post-vaccination autoimmunity. Favorable response to immunosuppressant was observed in all patients. In the current study, a temporal association between immunization with HPV vaccine and the appearance of a spectrum of SLE-like conditions is reported. Additionally, among the patients described, several common features were observed that may enable better identification of subjects at risk. Further studies are required to assess the safety of immunization with the HPV vaccine in patients with autoimmune-rheumatic diseases or in subject at risk of autoimmunity as well as the potential beneficial effect of preventive immunosuppressants.

Keywords

Anti-phospholipids antibodies ASIA Autoimmunity Human papillomavirus Systemic lupus erythematosus Vaccine 

References

  1. 1.
    Paavonen J (2007) Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int J Infect Dis 11(Suppl 2):S3–S9PubMedCrossRefGoogle Scholar
  2. 2.
    Carter JR, Ding Z, Rose BR (2011) HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol 51:103–108PubMedCrossRefGoogle Scholar
  3. 3.
    Jamal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefGoogle Scholar
  4. 4.
    Balofsky A, Agmon-Levin N, Shoenfeld Y (2010) The new H1N1 and HPV vaccines and old fears. Curr Opin Rheumatol 22:431–436PubMedCrossRefGoogle Scholar
  5. 5.
    Descamps D, Hardt K, Spiessens B et al (2009) Safety oh human papilloma virus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccine 5:332–340CrossRefGoogle Scholar
  6. 6.
    Ault KA (2007) Future II study group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861–1868PubMedCrossRefGoogle Scholar
  7. 7.
    Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928–1943PubMedCrossRefGoogle Scholar
  8. 8.
    Brown DR, Kjaer SK, Sigurdsson K et al (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. Infect Dis 199:926–935CrossRefGoogle Scholar
  9. 9.
    Harper DM, Franco EL, Wheeler CM et al (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247–1255PubMedCrossRefGoogle Scholar
  10. 10.
    Slade BA, Leidel L, Vellozzi C et al (2009) Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 302:750–757PubMedCrossRefGoogle Scholar
  11. 11.
    Franco EL, Harper DM (2005) Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 23:2388–2394PubMedCrossRefGoogle Scholar
  12. 12.
    Tomljenovic L, Shaw CA (2012) Too fast or not too fast: the FDA's approval of Merck's HPV vaccine Gardasil. J Law Med Ethics 40:673–681PubMedGoogle Scholar
  13. 13.
    Orbach H, Agmon-Levin N, Zandman-goddard G (2010) Vaccines and autoimmune diseases of the adult. Discov Med 9:90–97PubMedGoogle Scholar
  14. 14.
    Verstraeten T, Descamps D, David MP et al (2008) Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 26:6630–6638PubMedCrossRefGoogle Scholar
  15. 15.
    Soldevilla HF, Briones SF, Navarra SV (2012) Systemic lupus erythematosus following HPV immunization or infection? Lupus 21:158–161PubMedCrossRefGoogle Scholar
  16. 16.
    Cui H, Xue H, Yang L, Liu D, Qi L, Zhang N (2012) Missense polymorphisms within IL-10R1 exons are not associated with systemic lupus erythematosus in Chinese. Lupus 21:1232–1236PubMedCrossRefGoogle Scholar
  17. 17.
    Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y (2012) Systemic lupus erythematosus one disease or many? Autoimmun Rev 11:593–595PubMedCrossRefGoogle Scholar
  18. 18.
    Strickland FM, Hewagama A, Lu Q et al (2012) Environmental exposure, estrogen and two X chromosomes are required for disease development in an epigenetic model of lupus. J Autoimmun 38:J135–J143PubMedCrossRefGoogle Scholar
  19. 19.
    Gatto M, Zen M, Ghirardello A et al (2013) Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 12(4):523–536PubMedCrossRefGoogle Scholar
  20. 20.
    Bijl M, Agmon-Levin N, Dayer JM, Israeli E, Gatto M, Shoenfeld Y (2012) Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev 11:572–576PubMedCrossRefGoogle Scholar
  21. 21.
    Agmon-Levin N, Paz Z, Israeli E et al (2009) Vaccines and autoimmunity. Nat Rev Rheumatol 5:648–652PubMedCrossRefGoogle Scholar
  22. 22.
    Doria A, Canova M, Tonon M et al (2008) Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 8:24–28PubMedCrossRefGoogle Scholar
  23. 23.
    Agmon-Levin N, Zafrir Y, Paz Z et al (2009) Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus 18:1192–1197PubMedCrossRefGoogle Scholar
  24. 24.
    Stübgen JP (2012) Immune-mediated myelitis following hepatitis B vaccination. Autoimmun Rev 12(2):144–149PubMedCrossRefGoogle Scholar
  25. 25.
    Nohynek H, Jokinen J, Partinen M et al (2012) AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 7:e33536PubMedCrossRefGoogle Scholar
  26. 26.
    Saad CG, Borba EF, Aikawa NE et al (2011) Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 70(6):1068–1073PubMedCrossRefGoogle Scholar
  27. 27.
    Shoenfeld Y, Agmon-levin N (2011) 'ASIA'—autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 36:4–8PubMedCrossRefGoogle Scholar
  28. 28.
    Israeli E, Agmon-Levin N, Blank M et al (2009) Adjuvants and autoimmunity. Lupus 18:1217–1225PubMedCrossRefGoogle Scholar
  29. 29.
    Doria A, Iaccarino L, Ghirardello A et al (2006) Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 119:700–706PubMedCrossRefGoogle Scholar
  30. 30.
    Lyrio LD, Grassi MF, Santana IU et al (2013) Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int 33(2):335–340PubMedCrossRefGoogle Scholar
  31. 31.
    Klumb EM, Pinto AC, Jesus GR et al (2010) Are women with lupus at higher risk of HPV infection? Lupus 19:1485–1491PubMedCrossRefGoogle Scholar
  32. 32.
    Doria A, Briani C (2008) Lupus: improving long-term prognosis. Lupus 17:166–170PubMedCrossRefGoogle Scholar
  33. 33.
    Doria A, Zen M, Canova M et al (2010) SLE diagnosis and treatment: when early is early. Autoimmun Rev 10:55–60PubMedCrossRefGoogle Scholar
  34. 34.
    Mok CC, Ho LY, Fong LS, To CH (2012) Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case–control study. Ann Rheum Dis [Epub ahead of print]Google Scholar
  35. 35.
    Conti F, Rezai S, Valesini G (2008) Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 8:124–128PubMedCrossRefGoogle Scholar
  36. 36.
    Chang J, Campagnolo D, Vollmer TL, Bomprezzi R (2011) Demyelinating disease and polyvalent human papillomavirus vaccination. J Neurol Neurosurg Psychiatry 82:1296–1298PubMedCrossRefGoogle Scholar
  37. 37.
    Souayah N, Michas-martin PA, Nasar A et al (2011) Guillain–Barré syndrome after Gardasil vaccination: data from vaccine. Adverse Event Reporting System 2006–2009. Vaccine 29:886–889PubMedCrossRefGoogle Scholar
  38. 38.
    Sutton I, Lahoria R, Tan I, Clouston P, Barnett M (2009) CNS demyelination and quadrivalent HPV vaccination. Mult Scler 15:116–119PubMedCrossRefGoogle Scholar
  39. 39.
    Future I/II Study Group, Dillner J, Kjaer SK, Wheeler CM et al (2010) Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341:c3493PubMedCrossRefGoogle Scholar
  40. 40.
    Chao C, Klein NP, Velicer CM et al (2012) Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 271:193–203PubMedCrossRefGoogle Scholar
  41. 41.
    Tomljenovic L, Shaw CA (2012) No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil? J Intern Med 271(2):193–203CrossRefGoogle Scholar
  42. 42.
    van Assen S, Agmon-Levin N, Elkayam O et al (2011) EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70:414–422PubMedCrossRefGoogle Scholar
  43. 43.
    van Assen S, Bijl M (2012) Immunization of patients with autoimmune inflammatory rheumatic diseases (the EULAR recommendations). Lupus 21:162–167PubMedCrossRefGoogle Scholar
  44. 44.
    Soriano A, Manna R (2012) Quantifying the efficacy of influenza vaccine. Lancet Infect 12:659–660CrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2013

Authors and Affiliations

  • Mariele Gatto
    • 1
  • Nancy Agmon-Levin
    • 2
    • 3
  • Alessandra Soriano
    • 4
  • Raffaele Manna
    • 4
  • Ramit Maoz-Segal
    • 2
  • Shaye Kivity
    • 2
    • 3
    • 5
  • Andrea Doria
    • 1
  • Yehuda Shoenfeld
    • 2
    • 3
    • 6
  1. 1.Department of MedicineUniversity of PadovaPadovaItaly
  2. 2.The Zabludowicz Center for Autoimmune DiseasesSheba Medical CenterTel HashomerIsrael
  3. 3.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  4. 4.Periodic Fever Research CentreCatholic University of Sacred HeartRomeItaly
  5. 5.Rheumatic Disease UnitSheba Medical CenterTel HashomerIsrael
  6. 6.Sackler Faculty of Medicine, Incumbent of the Laura Schwarz-Kip Chair for Research of Autoimmune DiseasesTel Aviv UniversityTel AvivIsrael

Personalised recommendations